CYTK Cytokinetics Incorporated

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
EN
05/10/2020

Underlying

CYTKCytokinetics Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytokinetics Incorporated

 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces European Commission Approval of MYQORZO® (afica...

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructi...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at...

February 12, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces Recipients of Its Eighth Annual Communications ...

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eighth annual Communications Grant Program, intended to support increased communications, awareness building and community engagement. Two grants were awarded this year to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) community. The ...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team ...

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM) “On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the HCM community. The campaign features four-t...

January 27, 2026 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. ...

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S....

January 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch